NCT03519308

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to look at the potential effects of paricalcitol (a drug similar to vitamin D) and nivolumab on pancreatic tumors in patients who are treated with gemcitabine and abraxane. The study will also look at the safety of including paricalcitol and nivolumab as part of the gemcitabine and abraxane chemotherapeutic regimen.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Nivolumab	Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3
DRUG	Nab-Paclitaxel	Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
DRUG	Gemcitabine	Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
DRUG	Paricalcitol	Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery

Timeline

• Start date: 2020-07-29
• Primary completion: 2022-04-18
• Completion: 2022-04-18
• First posted: 2018-05-08
• Last updated: 2024-03-15
• Results posted: 2024-03-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study